No increase in the dose of Yorvipath or the placebo in the last four weeks Maintained a dose of 30 mcg per day or less of Yorvipath or the placebo throughout the entire 26-week study At 26 weeks ...

Leading Australian Endocrinologist and Head of the School of Clinical Sciences at Monash Health, Professor Peter Ebeling AO, applauded the TGA approval of YORVIPATH in addressing an unmet medical ...

Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic hypoparathyroidism in adults”. YORVIPATH was granted an ...

Mikkelsen announced the commercial launch of YORVIPATH in the U.S., with 908 unique patient prescriptions as of February 7, 2025. The product targets the treatment of hypoparathyroidism and is ...

SINGAPORE, Feb. 20, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by the Therapeutic ...